Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide

Survival of patients with metastatic prostate cancer and comorbid obesity.

(2022) Nina Cheranda et al.   JOURNAL OF CLINICAL ONCOLOGY

Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805

(2022) Alicia K. Morgans et al.   PROSTATE

Direct medical costs of obesity in the United States and the most populous states

(2021) John Cawley et al.   Journal of Managed Care & Specialty Pharmacy

TAXOMET: A French prospective multicentric randomized phase II study of docetaxel plus metformin versus docetaxel plus placebo in metastatic castration-resistant prostate cancer

(2021) PUJALTE MARTIN Marc et al.   Clinical Genitourinary Cancer

The obesity paradox in metastatic castration-resistant prostate cancer

(2021) Alberto Martini et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system

(2020) Paul Riviere et al.   CANCER

Obesity, race, and long‐term prostate cancer outcomes

(2020) Adriana C. Vidal et al.   CANCER

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

(2019) Gerhardt Attard et al.   JAMA Oncology

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

(2018) Adriana C. Vidal et al.   BJU INTERNATIONAL

Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy

(2018) Kyle A. Richards et al.   JOURNAL OF UROLOGY

Postdiagnosis Weight Change and Survival Following a Diagnosis of Early-Stage Breast Cancer

(2016) Elizabeth M. Cespedes Feliciano et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Uncontrolled diabetes predicts poor response to novel antiandrogens

(2016) Theodoros Karantanos et al.   ENDOCRINE-RELATED CANCER

Diabetes and Cancer: a Review of Current Knowledge

(2016) J. Wojciechowska et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis

(2015) A D Raval et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study

(2014) A. C. Vidal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer

(2014) R. J. Auchus et al.   ONCOLOGIST

Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality

(2012) Daniel E. Spratt et al.   EUROPEAN UROLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer cachexia: impact, mechanisms and emerging treatments

(2012) Vanessa C. Vaughan et al.   Journal of Cachexia Sarcopenia and Muscle

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

(2011) Rahul R. Aggarwal et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer

(2010) J. Flanagan et al.   ANNALS OF ONCOLOGY

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

(2008) Jing Ma et al.   LANCET ONCOLOGY